Northwest Biotherapeutics, Inc. (NWBO)

0.23
OTC Markets
Prev Close 0.23
Day Low/High 0.23 / 0.23
52 Wk Low/High 0.17 / 0.35
Exchange OTC Markets
Shares Outstanding 544.47B
Market Cap 124.68M
Div & Yield N.A. (N.A)
Northwest Biotherapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Northwest Biotherapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. - NWBO

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. - NWBO

Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Northwest Biotherapeutics, Inc.

Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)

Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)

Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.

Northwest Biotherapeutics Becomes Oversold (NWBO)

Northwest Biotherapeutics Becomes Oversold (NWBO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Northwest Bio Shareholders May Have Been Undercut by CEO

Northwest Bio Shareholders May Have Been Undercut by CEO

The loans negotiated by CEO Linda Powers to a private firm she controls doesn't appear to violate securities laws, but she may have breached fiduciary duty to Northwest Bio shareholders.

Interesting NWBO Put And Call Options For June 2016

Interesting NWBO Put And Call Options For June 2016

Investors in Northwest Biotherapeutics Inc saw new options become available today, for the June 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 360 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Commit To Purchase Northwest Biotherapeutics At $5, Earn 27% Using Options

Commit To Purchase Northwest Biotherapeutics At $5, Earn 27% Using Options

Investors eyeing a purchase of Northwest Biotherapeutics Inc shares, but cautious about paying the going market price of $8.50/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $5 strike, which has a bid at the time of this writing of $1.35.

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Jim Cramer's 'Mad Money' Recap: 5 'What If' Scenarios That Could Change Markets

Jim Cramer's 'Mad Money' Recap: 5 'What If' Scenarios That Could Change Markets

Every good investor needs to challenge his or her thinking, Cramer says.

U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?

U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?

Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.

Interesting NWBO Put And Call Options For February 20th

Interesting NWBO Put And Call Options For February 20th

Investors in Northwest Biotherapeutics Inc saw new options begin trading this week, for the February 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new February 20th contracts and identified one put and one call contract of particular interest.

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Another crazy and profitable year in biotech investing was captured 140 characters at a time.

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?

Interesting NWBO Put And Call Options For July 2015

Interesting NWBO Put And Call Options For July 2015

Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the July 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 227 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Washington Post’s Pearlstein Didn't Intend to Disparage TheStreet’s Integrity

Washington Post’s Pearlstein Didn't Intend to Disparage TheStreet’s Integrity

Steven Pearlstein, columnist for the Washington Post, says he never meant to disparage TheStreet's editorial standards in his Sept. 27 column examining TheStreet's Northwest Bio coverage.

Why Northwest Bio Is Shunned by Savvy Health Care Investors

Why Northwest Bio Is Shunned by Savvy Health Care Investors

If Northwest Bio's cancer vaccines -- DCVax-L and DCVax Direct -- are so promising, hedge funds should be falling over themselves to own the stock, not short it.

TheStreet Seeks Retraction From Washington Post on Steven Pearlstein Column

TheStreet Seeks Retraction From Washington Post on Steven Pearlstein Column

TheStreet has requested the Washington Post retract a column questioning the integrity of TheStreet's biotech coverage and its reporter Adam Feuerstein.

Relative Strength Alert For Northwest Biotherapeutics

Relative Strength Alert For Northwest Biotherapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Northwest Bio's Almost-Toxic Debt Raise Responsible for Stock Slide

Northwest Bio's Almost-Toxic Debt Raise Responsible for Stock Slide

The buyers of Northwest's debt want the stock price to decline before Feb. 15, 2015, because a lower stock price also will drop the conversion price of the notes.

Northwest Bio Can't Keep Its DC-Vax Claims Straight

Northwest Bio Can't Keep Its DC-Vax Claims Straight

Contradictory statements made on whether or not Northwest Bio conducted an interim analysis of its DC-Vax phase III study.

Northwest Bio DC-Vax Study Changes Hint at Failure

Northwest Bio DC-Vax Study Changes Hint at Failure

It's obvious DC-Vax came up futile in the early look at the phase III study data, leaving almost no chance the experimental cancer vaccine would benefit patients.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Northwest Biotherapeutics, Inc. Stockholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Northwest Biotherapeutics, Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against Northwest Biotherapeutics, Inc.

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

INVESTOR ALERT – Andrews & Springer LLC Is Investigating Northwest Biotherapeutics, Inc. For Possible Violations Of Securities Laws - NWBO

INVESTOR ALERT – Andrews & Springer LLC Is Investigating Northwest Biotherapeutics, Inc. For Possible Violations Of Securities Laws - NWBO

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud claims against Northwest Biotherapeutics, ...

5 Stocks Under $10 Setting Up to Soar

5 Stocks Under $10 Setting Up to Soar

These under-$10 stocks look poised to break out and trade higher from current levels.

Hospital Doubles Down on Northwest Bio's Cancer Vax Disclosure Criticism

Hospital Doubles Down on Northwest Bio's Cancer Vax Disclosure Criticism

MD Anderson released a statement criticizing Northwest Bio on Friday night after company shareholders and supporters flamed the hospital's Facebook page with hateful comments.

Northwest Bio Fails to Refute MD Anderson Rebuke

Northwest Bio Fails to Refute MD Anderson Rebuke

Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.